Mizuho analyst Salim Syed raised the firm’s price target on Atara Biotherapeutics (ATRA) to $18 from $16 and keeps an Outperform rating on the shares. The firm said it raised its price target on decreased operating expense, adding that it is watching the January 10, 2026 PDUFFA date for tab-cel and any word on the company’s strategic alternatives valuation.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ATRA:
- Atara Biotherapeutics price target raised to $140 from $131 at Mizuho
- Potential FDA Approval of Atara’s Tab-cel Therapy: A Game-Changer for Future Growth and CAR T Program Revitalization
- Atara Biotherapeutics reports Q3 EPS (32c), consensus (67c)
- Atara Biotherapeutics reduces workforce by 29%
- Pierre Fabre announces transfer of BLA for tabelecleucel from Atara Biotherapeutics